DUBLIN , July 27,
2022 /PRNewswire/ -- Perrigo Company plc (NYSE:
PRGO), a leading provider of Consumer Self-Care Products,
today announced that it will release its second quarter 2022
financial results on Tuesday, August 9,
2022. The Company will also host a conference call beginning
at 8:30 A.M. (EDT).
The conference call will be available live via webcast to
interested parties in the investor relations section of the Perrigo
website at http://perrigo.investorroom.com/events-webcasts or by
phone at 888-317-6003, International 412-317-6061, and reference ID
# 4031017. A taped replay of the call will be available beginning
at approximately 12:00 P.M. (EDT)
Tuesday, August 9, until midnight Tuesday, August 16, 2022. To listen to the
replay, dial 877-344-7529, International 412-317-0088, and use
access code 3460338.
About Perrigo
Perrigo Company plc (NYSE; PRGO) is a leading provider of
Consumer Self-Care Products and over-the-counter (OTC)
health and wellness solutions that enhance individual well-being by
empowering consumers to proactively prevent or treat conditions
that can be self-managed. Visit Perrigo online at
www.perrigo.com.
Forward-Looking
Statements
Certain statements in this press release are "forward-looking
statements." These statements relate to future events or the
Company's future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those
expressed or implied by any forward-looking statements. In some
cases, forward-looking statements can be identified by terminology
such as "may," "will," "could," "would," "should," "expect,"
"forecast," "plan," "anticipate," "intend," "believe," "estimate,"
"predict," "potential" or the negative of those terms or other
comparable terminology. The Company has based these forward-looking
statements on its current expectations, assumptions, estimates and
projections. While the Company believes these expectations,
assumptions, estimates and projections are reasonable, such
forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond the
Company's control, including: the effect of the coronavirus
(COVID-19) pandemic and its variants and associated supply chain
impacts on the Company's business; general economic, credit, and
market conditions; the impact of the war in Ukraine and any escalation thereof, including
the effects of economic and political sanctions imposed by
the United States, United Kingdom, European Union, and other
countries related thereto; the outbreak or escalation of conflict
in other regions where we do business; future impairment charges;
customer acceptance of new products; competition from other
industry participants, some of whom have greater marketing
resources or larger market shares in certain product categories
than the Company does; pricing pressures from customers and
consumers; resolution of uncertain tax positions, including the
Company's appeal of the draft and final Notices of Proposed
Assessment ("NOPAs") issued by the U.S. Internal Revenue Service
and the impact that an adverse result in any such proceedings would
have on operating results, cash flows, and liquidity; pending and
potential third-party claims and litigation, including litigation
relating to the Company's restatement of previously-filed financial
information and litigation relating to uncertain tax positions,
including the NOPAs; potential impacts of ongoing or future
government investigations and regulatory initiatives; uncertainty
regarding anticipated regulatory approvals; potential costs and
reputational impact of product recalls or sales halts; the impact
of tax reform legislation and/or changes in healthcare policy; the
timing, amount and cost of any share repurchases; fluctuations in
currency exchange rates and interest rates; the Company's ability
to achieve the benefits expected from the sale of its Rx business
and the risk that potential costs or liabilities incurred or
retained in connection with the transaction may exceed the
Company's estimates or adversely affect the Company's business or
operations; the Company's ability to achieve the benefits expected
from the acquisition of HRA Pharma and the risks that the Company's
synergy estimates are inaccurate or that the Company faces higher
than anticipated integration or other costs in connection with the
acquisition; risks associated with the integration of HRA Pharma,
including the risk that growth rates are adversely affected by any
delay in the integration of sales and distribution networks; the
consummation and success of other announced and unannounced
acquisitions or dispositions, and the Company's ability to realize
the desired benefits thereof; and the Company's ability to execute
and achieve the desired benefits of announced cost-reduction
efforts and strategic and other initiatives, including the
Company's ability to achieve the expected benefits from its supply
chain reinvention program. An adverse result with respect to the
Company's appeal of any material outstanding tax assessments or
pending litigation, including securities or drug pricing matters,
could ultimately require the use of corporate assets to pay such
assessments, damages from third-party claims, and related interest
and/or penalties, and any such use of corporate assets would limit
the assets available for other corporate purposes. There can be no
assurance that the FDA will approve the sale of daily oral
contraceptives without a prescription in the United States. These and other important
factors, including those discussed under "Risk Factors" in the
Company's Form 10-K for the year ended December 31, 2021, as well as the Company's
subsequent filings with the United States Securities and Exchange
Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these
forward-looking statements. The forward-looking statements in this
press release are made only as of the date hereof, and unless
otherwise required by applicable securities laws, the Company
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/perrigo-to-release-second-quarter-2022-financial-results-on-august-9-2022-301594299.html
SOURCE Perrigo Company plc